Evotec Alzheimer's Drug Well Tolerated in Trial
Posted on: Monday, 6 February 2006, 15:00 CST
Evotec AG has completed the single ascending dose component of the phase I clinical study evaluating its drug candidate EVT 101 for the treatment of Alzheimer's disease.
The study in 48 young healthy subjects, of whom 36 received EVT 101, showed that the drug was well absorbed, extremely well tolerated with no significant adverse events, and had a good pharmacokinetic profile consistent with once- or twice-daily oral dosing.
EVT 101 is a selective antagonist of the NMDA receptor. The positive safety profile of the drug suggested in this trial is significant as non-selective NMDA receptor antagonists are associated with an unfavorable side-effect profile.
The company has now moved the drug into the multiple ascending dose stage of the phase I study in both young and elderly volunteers. Evotec said that it expects to publish final results of the complete phase I trials for EVT 101 in the third quarter of 2006.
Source: Datamonitor
Related Articles
- Evotec's EVT 101 Well Tolerated in Four Week Higher Repeat Dose Safety Study
- Omeros Initiates Enrollment in Phase I Study of Urological Surgery Drug
- Mologen to Start Phase I Study of Cancer Drug
- Hadasit, Hadassah Medical Organization and Brigham and Women's Hospital Announce the Successful Phase I Study Results of a New Orally Administered Drug for Autoimmune Diseases
- Pharmacopeia's Hypertension Drug Found Effective in Phase I Study
- Cardiome Initiates Phase I Study of Cardiovascular Drug
- KaloBios Initiates a U.S. Phase 1 Study of Its Second Drug Candidate, KB001
- XTL Drug Safety Established in Phase I Study
- Dendreon Announces Publication of Pivotal Phase 3 Study Highlighting Survival Benefit and Safety Profile of PROVENGE in Men With Advanced Prostate Cancer
- Evotec Announces Initiation of Phase I Clinic Trial With EVT 101
 |
 |
User Comments (0)
RSS Feeds